OpGen, Inc. Stock News

ROCKVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics , which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance (AMR), entered into a strategic database access transaction with an unnamed global corporation and leader in microbiology and infectious disease diagnostics. Under the terms of the agreement, the unnamed IVD corporation gains immediate, permanent, unrestricted and non-exclusive access to a small subset constituting approximately 1.1% of the total current database content of Ares Genetics proprietary ARESdb.

Renaissance Technologies LLC raised its position in OpGen, Inc. (NASDAQ:OPGN) by 502.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,753 shares of the medical research companys stock after buying an additional 72,353 shares during the period. Renaissance Technologies LLCs []

During the last session, OpGen Inc. (NASDAQ:OPGN)s traded shares were 0.43 million, with the beta value of the company hitting -0.77. At the end of the trading day, the stocks price was $1.58, reflecting an intraday loss of -4.24% or -$0.07. The 52-week high for the OPGN share is $4.37, that puts it down -176.58 Boom Or Bust: Where Does OpGen Inc. (NASDAQ: OPGN) Stock Go From Here? Read More »

OpGen, Inc. (OPGN) with the stream of -4.24% also noticed, India Americas Gold and Silver Corporation (USAS) encountered a rapid change of -8.58% in the last hour of Fridays trading The post Top Stock Picks for the Day: OpGen, Inc. (NASDAQ:OPGN), Americas Gold and Silver Corporation (AMEX:USAS) appeared first on Stocks Equity .

Vanguard Group Inc. raised its holdings in shares of OpGen, Inc. (NASDAQ:OPGN) by 7.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,381,207 shares of the medical research companys stock after buying an additional 91,740 shares during the quarter. Vanguard Group []

OpGen, Inc. (NASDAQ:OPGN) CEO Oliver Schacht acquired 10,000 shares of the businesss stock in a transaction on Thursday, November 18th. The stock was acquired at an average price of $1.50 per share, with a total value of $15,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. []

OpGen, Inc. (NASDAQ:OPGN) CEO Oliver Schacht acquired 10,000 shares of the stock in a transaction that occurred on Thursday, November 18th. The shares were bought at an average price of $1.50 per share, with a total value of $15,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Schonfeld Strategic Advisors LLC lessened its holdings in shares of OpGen, Inc. (NASDAQ:OPGN) by 50.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,900 shares of the medical research companys stock after selling 24,000 shares during the period. Schonfeld Strategic []

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q3 2021 Results - Earnings Call Transcript

ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinform

ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinform

The FDA has granted 510(k) clearance to OpGen Inc's (NASDAQ: OPGN) Acuitas AMR Gene Panel. The Company is finalizing preparations for its commercial launch in the U.S. in Q4 of 2021.

Shares of OpGen Inc. OPGN, -4.17% rocketed 31.9% in active premarket trading Monday, after the precision medicine company provided a revenue update following the recent Food and Drug Administration cl